These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9070337)

  • 1. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study.
    Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E
    Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
    Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
    J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
    Takeuchi S; Saitoh H
    Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases].
    Takeuchi S; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.
    Sano M; Kushida K; Takahashi M; Ohishi T; Kawana K; Okada M; Inoue T
    Br J Cancer; 1994 Oct; 70(4):701-3. PubMed ID: 7917922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I; Miura T; Kondo I
    Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
    Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
    BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
    Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
    Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
    Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
    J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma.
    Yoshida K; Hosoya Y; Arai K; Sumi S; Honda M
    Clin Chim Acta; 1996 Oct; 254(1):93-5. PubMed ID: 8894314
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study.
    Hassager C; Colwell A; Assiri AM; Eastell R; Russell RG; Christiansen C
    Clin Endocrinol (Oxf); 1992 Jul; 37(1):45-50. PubMed ID: 1424192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism.
    Ohishi T; Takahashi M; Kushida K; Horiuchi K; Ishigaki S; Inoue T
    Endocr Res; 1992; 18(4):281-90. PubMed ID: 1473521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption.
    Nemoto R; Nakamura I; Nishijima Y; Shiobara K; Shimizu M; Takehara T; Ohta T; Kiyoki M
    Br J Urol; 1997 Aug; 80(2):274-80. PubMed ID: 9284202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
    Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
    J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma.
    Takeuchi S; Saitoh H
    Int J Urol; 1997 Jul; 4(4):368-73. PubMed ID: 9256326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.